Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 77, Issue 2, 2006, Pages 203-207

  Owe, J F ^a,b   Daltveit, A K ^a,c   Gilhus, N E ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DEATH CERTIFICATE; FEMALE; GROUPS BY AGE; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; NORWAY; PRIORITY JOURNAL; REGISTER; RESPIRATORY TRACT DISEASE; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; CAUSE OF DEATH; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; NORWAY; RESPIRATORY TRACT DISEASES; SEX FACTORS;

EID: 32344452103     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2005.072355     Document Type: Article

References (35)

1. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001;357:2122-8.
2. Romi F, Skeie GO, Aarli JA, et al. Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol 2000;247:369-75.
3. McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004;55:580-4.
4. Lindstrom J. Is "seronegative" MG explained by autoantibodies to MuSK? Neurology 2004;62:1920-1.
5. Phillips LH, Torner JC. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology 1996;47:1233-8.
6. Storm-Marthisen A. Epidemiology of myasthenia gravis in Norway. Acta Neurol Scand 1984;70:274-84.
7. Thorlacius S, Aarli JA, Ruse T, et al. Associated disorders in myasthenia gravis - autoimmune diseases and their relation to thymectomy. Acta Neurol Scand 1989;80:290-5.
8. Christensen PB, Jensen TS, Tsiropoulos I, et al. Mortality and survival in myasthenia gravis: a Danish population based study. J Neurol Neurosurg Psychiatry 1998;64:78-83.
9. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:7-15.
10. Evoli A, Minisci C, Di Schino C, et al. Thymoma in patients with MG: characteristics and long-term outcome. Neurology 2002;59:1844-50.
11. Evoli A, Punzi C, Marsili F, et al. Extrathymic malignancies in patients with thymoma. Ann Oncol 2004;15:692-3.
12. Pan CC, Chen PC, Wang LS, et al. Thymoma is associated with an increased risk of second malignancy. Cancer 2001;92:2406-11.
13. Somnier FE, Keiding N, Paulson OB. Epidemiology of myasthenia-gravis in Denmark - a longitudinal and comprehensive population Survey. Arch Neurol 1991;48:733-9.
14. Gjertsen F. (The cause of death registry and research.) Tidsskr Nor Laegeforen 2000;120:723-5.
15. Gjertsen F. (Cause of death registry - an important data source for medical research.) Tidsskr Nor Laegeforen, 2002;122:2551-4.
16. Cohen MS, Younger D. Aspects of the natural history of myasthenia gravis: crisis and death. Ann NY Acad Sci 1981;377:670-7.
17. Ertekin C, Yuceyar N, Aydogdu I. Clinical and electrophysiological evaluation of dysphagia in myasthenia gravis. J Neurol Neurosurg Psychiatry 1998;65:848-56.
18. Qureshi AI, Choundry MA, Mohammad Y, et al. Respiratory failure as a first presentation of myasthenia gravis. Med Sci Monit 2004;10:CR684-9.
19. Heliopoulos I, Panakas G, Vadikolias K, et al. Maximal voluntary ventilation in myasthenia gravis. Muscle Nerve 2003;27:715-19.
20. Ashworth B, Hunter AR. Respiratory failure in myasthenia gravis. Proc R Soc Med 1971;64:489-90.
21. Gracey DR, Divertie MB, Howard FM Jr. Mechanical ventilation for respiratory failure in myasthenia gravis. Two-year experience with 22 patients. Mayo Clin Proc 1983;58:597-602.
22. Tether JE. Management of myastheni and cholinergic crises. Am J Med 1955;19:740-2.
23. Thomas CE, Mayer SA, Gungor Y, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997;48:1253-60.
24. Aragones JM, Bolibar I, Bonfill X, et al. Myasthenia gravis: a higher than expected incidence in the elderly. Neurology 2003;60:1024-6.
25. Vincent A, Clover L, Buckley C, et al. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 2003;74:1105-8.
26. O'Riordan JI, Miller DH, Mottershead JP, et al. The management and outcome of patients with myasthenia gravis treated acutely in a neurological intensive care unit. Eur J Neurol 1998;5:137-42.
27. Luomanmaki K, Hokkanen E, Heikkila J. Electrocardiogram in myasthenia gravis. Analysis of a series of 97 patients. Ann Clin Res 1969;1:236-45.
28. Buyukozturk K, Ozdemir C, Kohen D. Electrocardiographic findings in 24 patients with myasthenia gravis. Acta Cardiol 1976;31:301-5.
29. Hofstad H, Ohm OJ, Mark SJ, et al. Heart disease in myasthenia gravis. Acta Neurol Scand 1984;70:176-84.
30. Tanahashi N, Sato H, Nogawa S, et al. A case report of giant cell myocarditis and myositis observed during the clinical course of invasive thymoma associated with myasthenia gravis. Keio J Med 2004;53:30-42.
31. Johannessen KA, Mygland A, Gilhus NE, et al. Left ventricular function in myasthenia gravis. Am J Cardiol 1992;69:129-32.
32. Bolognesi R, Vasini P, Tsialtas D, et al. Acute heart failure due to neoplastic invasion of ventricular myocardium by relapsing thymoma. Eur J Heart Fail 2001;3:113-16.
33. Cooper LT Jr. Giant cell myocarditis: diagnosis and treatment. Herz 2000;25:291-8.
34. Pentz WH. Advanced heart block as a manifestation of a paraneoplastic syndrome from malignant thymoma. Chest 1999;116:1135-6.
35. Romi F, Gilhus NE, Varhaug JE, et al. Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study. Eur J Neurol 2003;10:701-6.